Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Stein Bergan"'
Autor:
Trine Lauritzen, John Munkhaugen, Stein Bergan, Kari Peersen, Anja Camilla Svarstad, Anders M. Andersen, Jens Pahnke, Einar Husebye, Nils Tore Vethe
Publikováno v:
Atherosclerosis Plus, Vol 55, Iss , Pp 31-38 (2024)
Background and aims: Statin-associated muscle symptoms (SAMS) is a prevalent cause of statin discontinuation. It is challenging and time-consuming for clinicians to assess whether symptoms are caused by the statin or not, and diagnostic biomarkers ar
Externí odkaz:
https://doaj.org/article/f98394738ee04db2a3ec9c22ef5ac108
Autor:
Mercè Brunet, Eberhard Wieland, Alexander A. Vinks, Pierre Wallemacq, Nils Tore Vethe, Nicolas Picard, Dirk Jan A.R. Moes, Mariadelfina Molinaro, Paweł K. Kunicki, Klemens Budde, Satohiro Masuda, Maja Theresa Dieterlen, Tomoyuki Mizuno, Stein Bergan, Laure Elens, Anders Åsberg, Olga Millán, Florian Lemaitre, Burkhard Tönshoff, Maria Shipkova, Jesse J. Swen, Teun van Gelder, Tomasz Pawinski, Vincent Haufroid, Ofelia Noceti, Tom C. Zwart, Pierre Marquet, Smita Pattanaik, Jean-Baptiste Woillard, Loralie J. Langman, Markus J. Barten, Dennis A. Hesselink, Ron H.N. van Schaik, Michael Oellerich, Christoph Seger, Linda Salzmann, Kamisha L. Johnson-Davis, Raman Venkataramanan
Publikováno v:
Therapeutic Drug Monitoring, Vol. 43, no.2, p. 150-200 (2021)
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2021, 43 (2), pp.150-200. ⟨10.1097/FTD.0000000000000871⟩
Therapeutic Drug Monitoring, 2021, 43 (2), pp.150-200. ⟨10.1097/FTD.0000000000000871⟩
Therapeutic Drug Monitoring, 43(2), 150-200. LIPPINCOTT WILLIAMS & WILKINS
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2021, 43 (2), pp.150-200. ⟨10.1097/FTD.0000000000000871⟩
Therapeutic Drug Monitoring, 2021, 43 (2), pp.150-200. ⟨10.1097/FTD.0000000000000871⟩
Therapeutic Drug Monitoring, 43(2), 150-200. LIPPINCOTT WILLIAMS & WILKINS
When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b1cf2bb23290633f56b83d70251d51
https://hdl.handle.net/2078.1/249100
https://hdl.handle.net/2078.1/249100
Autor:
Morten W. Fagerland, Morten Lindberg, Kari Peersen, Einar Husebye, Stein Bergan, Erik Gjertsen, Nils Tore Vethe, Elise Sverre, Joep Perk, Toril Dammen, John Munkhaugen, Oskar Kristiansen, Elena Prunès Jensen, Lars Gullestad, Jan Erik Otterstad
Publikováno v:
European Heart Journal — Cardiovascular Pharmacotherapy
Aims To estimate the effect of atorvastatin on muscle symptom intensity in coronary heart disease (CHD) patients with self-perceived statin-associated muscle symptoms (SAMS) and to determine the relationship to blood levels of atorvastatin and/or met
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 139(8)
Autor:
Nils Tore Vethe, John Munkhaugen, Toril Dammen, Einar Husebye, Stein Bergan, Lars Gullestad, Jan Erik Otterstad, Joep Perk, Erik Gjertsen, Morten W. Fagerland
Objectives. Estimate the effect of atorvastatin on muscular symptom intensity in coronary patients with subjective statin-associated muscle symptoms (SAMS) and to determine the association with blood levels of atorvastatin and its metabolites, to obt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84bf5b49d38fa61b27772cf2e8b8b356
http://hdl.handle.net/10852/77799
http://hdl.handle.net/10852/77799
Autor:
Jean-Baptiste Woillard, Uwe Christians, Dirk Jan A.R. Moes, Claudia Sommerer, Nicolas Picard, Tomasz Pawinski, Brenda C. M. de Winter, Markus J. Barten, Tomoyuki Mizuno, Pierre Wallemacq, Florian Lemaitre, Kamisha L. Johnson-Davis, Nils Tore Vethe, Pierre Marquet, Binu S. Mathew, Ron H.N. van Schaik, Iain MacPhee, Loralie J. Langman, Dennis A. Hesselink, Christoph Seger, Teun van Gelder, Alexander A. Vinks, Paweł K. Kunicki, Vincent Haufroid, Stein Bergan, Klemens Budde, Satohiro Masuda, Mercè Brunet, Eberhard Wieland, Caroline Monchaud, Helena Colom, Maria Shipkova, Ofelia Noceti, Laure Elens, Olga Millán, Maja Theresa Dieterlen, Anders Åsberg
Publikováno v:
Therapeutic Drug Monitoring, 41(3), 261-307. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (3), pp.261-307. ⟨10.1097/FTD.0000000000000640⟩
Therapeutic Drug Monitoring, 41(3), 261-307
Therapeutic Drug Monitoring, 2019, 41 (3), pp.261-307. ⟨10.1097/FTD.0000000000000640⟩
Therapeutic drug monitoring, Vol. 41, no.3, p. 261-307 (2019)
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (3), pp.261-307. ⟨10.1097/FTD.0000000000000640⟩
Therapeutic Drug Monitoring, 41(3), 261-307
Therapeutic Drug Monitoring, 2019, 41 (3), pp.261-307. ⟨10.1097/FTD.0000000000000640⟩
Therapeutic drug monitoring, Vol. 41, no.3, p. 261-307 (2019)
International audience; Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e9f00168e1d0fa4d232dd8058bcdc16
https://pure.eur.nl/en/publications/111d5c63-b5aa-483e-a2b6-ea778ee98946
https://pure.eur.nl/en/publications/111d5c63-b5aa-483e-a2b6-ea778ee98946
Autor:
Teun van Gelder, Vincent Haufroid, Mercè Brunet, Eberhard Wieland, Michael Oellerich, Claudia Sommerer, Marcos López-Hoyos, Tomasz Pawinski, Pierre Wallemacq, Nicolas Picard, Olga López, D. A. Hesselink, Maria Shipkova, Uwe Christians, Markus J. Barten, Ofelia Noceti, P. Marquet, Klemens Budde, Stein Bergan
Publikováno v:
EUR Research Portal
Therapeutic Drug Monitoring, 38, S1-S20. Lippincott Williams & Wilkins
Therapeutic Drug Monitoring, 38, S1-S20. Lippincott Williams & Wilkins
With current treatment regimens, a relatively high proportion of transplant recipients experience underimmunosuppression or overimmunosuppression. Recently, several promising biomarkers have been identified for determining patient alloreactivity, whi
Publikováno v:
Therapeutic Drug Monitoring
Supplemental Digital Content is Available in the Text.
Background: Busulfan (Bu) and cyclophosphamide (Cy) are frequently included in conditioning regimens before hematopoietic stem cell transplantation (HSCT). Both drugs are detoxified by gluta
Background: Busulfan (Bu) and cyclophosphamide (Cy) are frequently included in conditioning regimens before hematopoietic stem cell transplantation (HSCT). Both drugs are detoxified by gluta
Publikováno v:
Journal of the American Medical Informatics Association. 21:e143-e146
The potential of pharmacogenomics is well documented, and functionality exploiting this knowledge is about to be introduced into electronic medical records. To explore physicians' reactions to automatic interpretations of genetic tests, we built a pr
Autor:
Teun van Gelder, Pierre Wallemacq, Nicolas Picard, Vincent Haufroid, Stein Bergan, Pierre Marquet, Dennis A. Hesselink
Publikováno v:
Therapeutic Drug Monitoring, 38, S57-S69. Lippincott Williams & Wilkins
EUR Research Portal
EUR Research Portal
In association with therapeutic drug monitoring of immunosuppressive drugs, pharmacogenetics has rapidly emerged as an additional tool to refine dose selection or, more interestingly to select, a priori, the first dose to administer. Pharmacogenetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a11c1b9eb52148c72a79d7ed660d19
https://pure.eur.nl/en/publications/4002049b-7e7d-494d-96da-6d5f751ed2ee
https://pure.eur.nl/en/publications/4002049b-7e7d-494d-96da-6d5f751ed2ee